PAVmed, Inc. (PAVM)

PAVmed's stock has been impacted by several events in the past six months. A 1-for-30 reverse stock split became effective on January 2, 2026. The stock price has declined by approximately 27.68% over the last six months and 67.31% over the last year. Lucid Diagnostics announced and closed an $18 million underwritten offering of common stock in April 2026. PAVmed held its Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026, and is scheduled to hold its First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026, while Lucid Diagnostics will hold its First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026. PAVmed reported a GAAP net income of $18.6 million for Q1 2025, primarily driven by the mark-to-market valuation of its equity method investment in Lucid Diagnostics, but a non-GAAP loss of $910,000 for Q1 2025. Full year 2025 earnings showed a loss of US$5.63 per share, a decrease from a profit in FY 2024.

Information specifically detailing demand seasonality for PAVmed's products and services was not found. However, there is an indication of increasing market demand for its diagnostic services, with a sequential increase in EsoGuard tests processed. The anticipated growth of newly commercialized products is also expected to contribute significantly to revenues in 2025 and 2026.

PAVmed Inc. is a diversified, commercial-stage medical technology company in the Healthcare sector, focusing on advancing medical technologies from concept to commercialization through multiple business lines and subsidiaries. Its primary lines of business include Diagnostics (cancer prevention and early detection), Medical Devices (development and commercialization of medical technologies), and Digital Health (digital cancer care and remote patient monitoring).

PAVmed Inc. is headquartered in New York, NY, United States. The company has a significant operational and market presence within the United States, including a U.S. Department of Veterans Affairs (VA) contract for EsoGuard.

PAVmed has maintained a positive brand reputation over the past year. Lucid Diagnostics announced the peer-reviewed publication of positive results from three clinical utility studies. PAVmed appointed Joseph Virgilio as Senior Vice President and Chief Business Officer of Medical Devices. Veris Health joined the CancerX Partnership as a founding member, and Lucid Diagnostics launched its first EsoGuard Mobile Test Unit and conducted a precancer testing event with the San Antonio Fire Department. No significant negative events impacting PAVmed's brand reputation in the past year were found in the search results.

PAVmed Inc.'s ownership structure includes a mix of institutional, insider, and public/individual investors. Approximately 0.34% of the company's stock is owned by Institutional Investors, 15.05% by Insiders, and 84.61% by Public Companies and Individual Investors. Major institutional owners include Captrust Financial Advisors, SBI Securities Co., Ltd., AdvisorNet Financial, Inc., First Manhattan CO. LLC, Geode Capital Management LLC, Jane Street Group LLC, The Vanguard Group, Inc., BlackRock, Inc., and UBS Group AG. Key individual insider owners include Ira Scott Greenspan, Matthew Sirovich, Lishan Aklog, Dennis M. McGrath, and Joshua R. Lamstein.